Australia's Kazia climbs on rare-disease tag for pediatric cancer drug

Kazia Therapeutics

06/07/2022 12:35

** US-listed shares of Australia's Kazia Therapeutics
 KZIA.O  rise ~15.3% to $4.81 premarket
    ** U.S. FDA grants rare pediatric disease designation to
paxalisib for treatment of atypical rhabdoid/teratoid tumors, a
type of childhood brain cancer  urn:newsml:reuters.com:*:nPn48j0jja
    ** Designation is granted to serious and life-threatening
diseases that primarily affect children aged 18 years or younger
    ** Designation qualifies Kazia to receive fast-track review,
and priority review voucher at the time of marketing approval of
paxalisib
    ** Stock is down 50.48% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))